The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.

The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.

Date of Patent:
Apr. 19, 2016

Filed:

Mar. 05, 2010
Applicants:

Bert Vogelstein, Baltimore, MD (US);

Kenneth W. Kinzler, Baltimore, MD (US);

D. Williams Parsons, Ellicott City, MD (US);

Sian Jones, Baltimore, MD (US);

Scott Kern, Hunt Valley, MD (US);

Ralph Hruban, Baltimore, MD (US);

James R. Eshleman, Lutherville, MD (US);

Michael Goggins, Baltimore, MD (US);

Alison Klein, Baltimore, MD (US);

Manuel Hidalgo, Baltimore, MD (US);

Victor E. Velculescu, Dayton, MD (US);

Inventors:

Bert Vogelstein, Baltimore, MD (US);

Kenneth W. Kinzler, Baltimore, MD (US);

D. Williams Parsons, Ellicott City, MD (US);

Sian Jones, Baltimore, MD (US);

Scott Kern, Hunt Valley, MD (US);

Ralph Hruban, Baltimore, MD (US);

James R. Eshleman, Lutherville, MD (US);

Michael Goggins, Baltimore, MD (US);

Alison Klein, Baltimore, MD (US);

Manuel Hidalgo, Baltimore, MD (US);

Victor E. Velculescu, Dayton, MD (US);

Assignee:

The Johns Hopkins University, Baltimore, MD (US);

Attorney:
Primary Examiner:
Int. Cl.
CPC ...
C12Q 1/68 (2006.01); C12P 19/34 (2006.01); A61P 35/00 (2006.01); G01N 33/574 (2006.01); C07H 21/04 (2006.01);
U.S. Cl.
CPC ...
C12Q 1/6886 (2013.01); G01N 33/57438 (2013.01); C12Q 2600/106 (2013.01); C12Q 2600/156 (2013.01);
Abstract

The present invention provides a method for detecting mutations in the PALB2 gene in pancreatic cancer patients and in individuals having a family history of pancreatic cancer. Methods are also provided for diagnosing a predisposition to pancreatic cancer, for predicting a patient's response to pancreatic cancer therapies, and for treating pancreatic cancer, based on presence of a PALB2 mutation or abberant PALB2 gene expression in a patient.


Find Patent Forward Citations

Loading…